Bloomberg Intelligence reports AbbVie's $10.9 billion acquisition of Apogee Therapeutics, which adds atopic dermatitis treatments to AbbVie's dermatology portfolio.
bloomberg-markets06/22, 09:12 PM
Related assets
Coming up for ABBV
Explore next
Latest ABBV news
FirstSquawk08/20, 09:57 AM
Piper Sandler raised its price target on AbbVie to $303 from $298.
Bloomberg08/17, 06:28 PM
Bloomberg08/03, 04:58 PM